Compare Equitable Holdings Inc. Common Stock (EQH) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equitable Holdings Inc. Common Stock vs Repligen Corporation Common Stock — how do they compare? Equitable Holdings Inc. Common Stock trades at $52.77 (market cap $14.49B), while Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B). The key difference: Equitable Holdings Inc. Common Stock is the larger of the two by market cap, and Equitable Holdings Inc. Common Stock pays a 2.15% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equitable Holdings Inc. Common Stock for 0 Days and Repligen Corporation Common Stock for 0 Days on average.
| EQH | RGEN | |
|---|---|---|
Market Cap | $14.49B | $11.14B |
Volume | 2,405,401 | 1,259,263 |
Sector | Financials | Health |
52-Week High | $54.50 | $194.57 |
52-Week Low | $35.34 | $102.87 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $5.54B | $11.02B |
Dividend Yield | 2.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equitable Holdings (EQH) trades at $53.12, down 0.75% on the day, with strong analyst support (95% buy ratings) and a $64.71 consensus price target suggesting 22% upside. Recent quarterly earnings have consistently beaten expectations, though the company reported a net loss of $1.38B for 2025. The planned merger with Corebridge and expansion into fee-based businesses are key growth drivers, while high debt-to-asset ratio of 2.07 presents financial risk.
EQH shows mixed fundamentals with positive earnings momentum but negative profitability metrics. The stock offers significant upside potential based on analyst targets, supported by strategic initiatives and dividend appeal. Key risks include execution of the Corebridge merger, persistent net losses, and high leverage. Investors should weigh strong analyst conviction against fundamental weaknesses.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equitable Holdings Inc. Common Stock
Equitable Holdings, Inc. is a financial services holding company operating through Equitable, AllianceBernstein, and Equitable Advisors. It provides retirement and protection products, asset and wealth management services, and financial planning through a network of registered financial professionals.
Read more on EQH →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
